NFX 179
Alternative Names: NFX-179Latest Information Update: 28 Nov 2024
At a glance
- Originator NFlection Therapeutics
- Class Antineoplastics; Chemopreventatives; Skin disorder therapies; Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neurofibromatosis 1
- No development reported Skin disorders; Squamous cell cancer
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Neurofibromatosis-1 in United Kingdom (Topical, Gel)
- 28 Nov 2024 No recent reports of development identified for preclinical development in Skin-disorders in United Kingdom (Topical, Gel)
- 28 Nov 2024 No recent reports of development identified for preclinical development in Squamous-cell-cancer in United Kingdom (Topical, Gel)